NZ577731A - Compositions and methods for treatment of multiple sclerosis - Google Patents

Compositions and methods for treatment of multiple sclerosis

Info

Publication number
NZ577731A
NZ577731A NZ577731A NZ57773109A NZ577731A NZ 577731 A NZ577731 A NZ 577731A NZ 577731 A NZ577731 A NZ 577731A NZ 57773109 A NZ57773109 A NZ 57773109A NZ 577731 A NZ577731 A NZ 577731A
Authority
NZ
New Zealand
Prior art keywords
multiple sclerosis
microparticle
treatment
mis416
linked
Prior art date
Application number
NZ577731A
Other languages
English (en)
Inventor
Frank B Gelder
Gillian Alison Webster
Original Assignee
Innate Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Therapeutics Ltd filed Critical Innate Therapeutics Ltd
Priority to NZ577731A priority Critical patent/NZ577731A/en
Priority to US12/639,733 priority patent/US8389479B2/en
Priority to CA2688766A priority patent/CA2688766C/en
Priority to CN201080026791.5A priority patent/CN102458476B/zh
Priority to BRPI1009606A priority patent/BRPI1009606A2/pt
Priority to PL10789788T priority patent/PL2442832T3/pl
Priority to ES10789788.6T priority patent/ES2521565T3/es
Priority to DK10789788.6T priority patent/DK2442832T3/da
Priority to SI201030779T priority patent/SI2442832T1/sl
Priority to HK12107888.6A priority patent/HK1167101B/en
Priority to PT107897886T priority patent/PT2442832E/pt
Priority to AU2010260585A priority patent/AU2010260585B2/en
Priority to HRP20141035AT priority patent/HRP20141035T1/hr
Priority to IN167DEN2012 priority patent/IN2012DN00167A/en
Priority to EP10789788.6A priority patent/EP2442832B1/en
Priority to MX2011013661A priority patent/MX2011013661A/es
Priority to JP2012516022A priority patent/JP5646617B2/ja
Priority to PCT/NZ2010/000112 priority patent/WO2010147484A1/en
Publication of NZ577731A publication Critical patent/NZ577731A/en
Priority to IL216993A priority patent/IL216993A/en
Priority to CY20141100908T priority patent/CY1115714T1/el
Priority to SM201400165T priority patent/SMT201400165B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Photographic Developing Apparatuses (AREA)
NZ577731A 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis NZ577731A (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
US12/639,733 US8389479B2 (en) 2009-06-16 2009-12-16 Compositions and methods for treatment of multiple sclerosis
CA2688766A CA2688766C (en) 2009-06-16 2009-12-17 Compositions and methods for treatment of multiple sclerosis
CN201080026791.5A CN102458476B (zh) 2009-06-16 2010-01-16 用于治疗多发性硬化症的组合物及方法
BRPI1009606A BRPI1009606A2 (pt) 2009-06-16 2010-01-16 método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição
HK12107888.6A HK1167101B (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis
EP10789788.6A EP2442832B1 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis
DK10789788.6T DK2442832T3 (da) 2009-06-16 2010-06-16 Sammensætninger og fremgangsmåder til behandling af dissemineret sclerose
SI201030779T SI2442832T1 (sl) 2009-06-16 2010-06-16 Sestavki in postopki za zdravljenje multiple skleroze
PL10789788T PL2442832T3 (pl) 2009-06-16 2010-06-16 Kompozycje i sposoby do leczenia stwardnienia rozsianego
PT107897886T PT2442832E (pt) 2009-06-16 2010-06-16 Composições e métodos para tratamento da esclerose múltipla
AU2010260585A AU2010260585B2 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of Multiple Sclerosis
HRP20141035AT HRP20141035T1 (hr) 2009-06-16 2010-06-16 Sastavi i metode za lijeäśenje multiple skleroze
IN167DEN2012 IN2012DN00167A (enExample) 2009-06-16 2010-06-16
ES10789788.6T ES2521565T3 (es) 2009-06-16 2010-06-16 Composiciones y métodos para el tratamiento de la esclerosis múltiple
MX2011013661A MX2011013661A (es) 2009-06-16 2010-06-16 Composiciones y metodos para el tratamiento de esclerosis multiple.
JP2012516022A JP5646617B2 (ja) 2009-06-16 2010-06-16 多発性硬化症の治療のための組成物および方法
PCT/NZ2010/000112 WO2010147484A1 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis
IL216993A IL216993A (en) 2009-06-16 2011-12-15 Pharmaceuticals Containing Microparticle Cross-linked Murmyl Peptide for the Treatment of Multiple Sclerosis
CY20141100908T CY1115714T1 (el) 2009-06-16 2014-11-03 Συνθεσεις και μεθοδοι για τη θεραπεια της πολλαπλης σκληρυνσης
SM201400165T SMT201400165B (it) 2009-06-16 2014-11-04 Composizioni e metodi per il trattamento di sclerosi multipla

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
NZ577731A true NZ577731A (en) 2010-08-27

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis

Country Status (20)

Country Link
US (1) US8389479B2 (enExample)
EP (1) EP2442832B1 (enExample)
JP (1) JP5646617B2 (enExample)
CN (1) CN102458476B (enExample)
AU (1) AU2010260585B2 (enExample)
BR (1) BRPI1009606A2 (enExample)
CA (1) CA2688766C (enExample)
CY (1) CY1115714T1 (enExample)
DK (1) DK2442832T3 (enExample)
ES (1) ES2521565T3 (enExample)
HR (1) HRP20141035T1 (enExample)
IL (1) IL216993A (enExample)
IN (1) IN2012DN00167A (enExample)
MX (1) MX2011013661A (enExample)
NZ (1) NZ577731A (enExample)
PL (1) PL2442832T3 (enExample)
PT (1) PT2442832E (enExample)
SI (1) SI2442832T1 (enExample)
SM (1) SMT201400165B (enExample)
WO (1) WO2010147484A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103990120B (zh) * 2008-04-01 2018-06-05 伊耐特免疫治疗有限公司 抗感染剂及其用途
EP3722808B1 (en) * 2010-10-25 2024-09-11 Biogen MA Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CA2926507A1 (en) * 2015-10-06 2017-04-06 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
WO2019218079A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
WO2020010221A1 (en) * 2018-07-03 2020-01-09 University Of Florida Research Foundation, Inc. Microparticle systems and their use for the treatment of multiple sclerosis
BR112022024966A2 (pt) * 2020-06-22 2023-01-03 Otivio As Métodos para tratar espasticidade usando composições antiespasmódicas e terapia de pressão negativa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU732809B2 (en) * 1996-10-10 2001-05-03 Innate Immunotherapeutics Limited Compositions and methods for treating viral infections
EA200700263A1 (ru) * 2004-07-01 2007-06-29 Кебенхавнс Университет Способ лечения и профилактики рассеянного склероза путём лечения лептоспирозной инфекции
WO2008070564A1 (en) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
JP2008251608A (ja) 2007-03-29 2008-10-16 Casio Comput Co Ltd 半導体装置およびその製造方法
WO2008150182A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax
WO2008150181A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions

Also Published As

Publication number Publication date
WO2010147484A1 (en) 2010-12-23
AU2010260585B2 (en) 2013-02-21
CY1115714T1 (el) 2017-01-25
JP5646617B2 (ja) 2014-12-24
ES2521565T3 (es) 2014-11-12
US20100317589A1 (en) 2010-12-16
IN2012DN00167A (enExample) 2015-04-17
AU2010260585A1 (en) 2012-01-19
EP2442832A1 (en) 2012-04-25
EP2442832A4 (en) 2013-07-03
US8389479B2 (en) 2013-03-05
SI2442832T1 (sl) 2014-12-31
JP2012530132A (ja) 2012-11-29
SMT201400165B (it) 2015-01-15
WO2010147484A8 (en) 2012-07-19
HK1167101A1 (en) 2013-02-01
BRPI1009606A2 (pt) 2016-10-11
CN102458476A (zh) 2012-05-16
EP2442832B1 (en) 2014-08-06
PT2442832E (pt) 2014-11-11
CA2688766C (en) 2015-06-30
DK2442832T3 (da) 2014-11-10
AU2010260585A8 (en) 2012-06-14
HRP20141035T1 (hr) 2014-12-19
IL216993A0 (en) 2012-02-29
CN102458476B (zh) 2014-08-20
MX2011013661A (es) 2012-05-22
PL2442832T3 (pl) 2015-01-30
CA2688766A1 (en) 2010-12-16
IL216993A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
AU2010260585B2 (en) Compositions and methods for treatment of Multiple Sclerosis
Arnason et al. Idiopathic polyneuritis after surgery
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
TW201119645A (en) Low frequency glatiramer acetate therapy
JP3806427B2 (ja) 新規鎮痛剤
WO2014019268A1 (zh) 一种促进神经损伤修复的药物组合物及其应用
JP2008519847A (ja) 運動障害の治療方法
Erman et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia
JP2001511121A (ja) コポリマー１の摂取又は吸入を通じての多発性硬化症の治療
JP2020500864A5 (enExample)
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
KR20200101948A (ko) 신경계 질환 치료제
KR20170131543A (ko) 근위축성 측삭 경화증을 치료하기 위한 비오틴
Bocci The clinical application of ozonetherapy
JP2018519362A (ja) 炎症性疾患の予防または治療用ペプチド及びこの用途
US20220395472A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
RU2180591C2 (ru) Средство для лечения сексуальных дисфункций у мужчин
HK1167101B (en) Compositions and methods for treatment of multiple sclerosis
CN111803487B (zh) 银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途
US20060020037A1 (en) Tazarotenic acid and esters thereof for treating autism
Sullivan-Whalen et al. Psoriasis: hope for the future
JP2021530567A (ja) 安息香酸塩または安息香酸誘導体を含む、抗ｎ−メチル−ｄ−アスパラギン酸受容体脳炎を予防または治療するための医薬組成物
CN110101845A (zh) 鸢尾素在制备防治术后认知功能障碍以及血脑屏障受损所介导脑病的药物中的应用
CN109999179A (zh) 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用
JP2023539391A (ja) セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用

Legal Events

Date Code Title Description
PSEA Patent sealed
S881 Correction of error according section 88(1) (mistake in register by reason of an error or omission on the part of the patent office)

Free format text: CORRECTION TO THE FILING DATE (22)

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 JUN 2017 BY SHELSTON IP

Effective date: 20140610

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 JUN 2018 BY SHELSTON IP PTY LTD

Effective date: 20170512

LAPS Patent lapsed